Your browser doesn't support javascript.
loading
Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor: reply.
Gerrits, A J; Jakubowski, J A; Michelson, A D; Frelinger, A L.
Affiliation
  • Gerrits AJ; Center for Platelet Research Studies, Division of Hematology/Oncology, Boston Children's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Jakubowski JA; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA.
  • Michelson AD; Center for Platelet Research Studies, Division of Hematology/Oncology, Boston Children's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Frelinger AL; Center for Platelet Research Studies, Division of Hematology/Oncology, Boston Children's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
J Thromb Haemost ; 16(3): 607-608, 2018 03.
Article in En | MEDLINE | ID: mdl-29314666
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Purinergic P2Y Receptor Antagonists / Ticagrelor Language: En Journal: J Thromb Haemost Journal subject: HEMATOLOGIA Year: 2018 Document type: Article Affiliation country: Estados Unidos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Purinergic P2Y Receptor Antagonists / Ticagrelor Language: En Journal: J Thromb Haemost Journal subject: HEMATOLOGIA Year: 2018 Document type: Article Affiliation country: Estados Unidos